BioSpace News Archive

Wilmington, Delaware, United States, Transparency Market Research Inc.: According to Transparency Market Research’s latest report on the global teleradiology market for the historical period 2017-2018 and forecast period 2019-2027, advancements in digital technology, rise in number of radiology imaging procedures are projected to drive the global teleradiology Market

CSL Limited is pleased to announce it has now received all necessary regulatory clearances for the acquisition of Vifor Pharma AG announced on 14 December 2021.

Vimian Group has acquired Heiland GmbH, a leading online ordering platform offering veterinary pharmaceuticals and other veterinary products to veterinary clinics across Germany.

IDRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision combination therapies, launched with a $122 million oversubscribed Series A financing.

Sage Therapeutics, Inc., a biopharmaceutical company leading the way to create a world with better brain health, reported business highlights and financial results for the second quarter ended June 30, 2022.

Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in oncology, announced today that the U.S. Patent and Trademark Office (USPTO) has granted the patent (Patent No. US 11,401,329) of its anti-CD47 antibodies.

AviadoBio, a pioneering, pre-clinical stage gene therapy company focused on developing and delivering transformative medicines for people with neurodegenerative disorders, announced the appointment of David Cooper, MD, MBA, as Chief Medical Officer.

Lucira Health, Inc. (“Lucira Health” or “Lucira”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced that the company will report second quarter 2022 financial results on, Monday, August 15, 2022.

Anavex Life Sciences Corp. announced long-lasting effect of clinical drug candidate ANAVEX®3-71 in preventing cognitive decline in a transgenic rat model of Alzheimer’s disease at the Alzheimer’s Association International Conference, taking place in San Diego, CA and virtually on July 31 – August 4, 2022.

EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, announced that EyePoint Pharmaceuticals’ will present at the following upcoming conferences.